Current opinion on an emergence of drug resistant strains of Plasmodium falciparum through genetic alterations

Kondapalli Kasturi*, Donepudi Siva Mallika, Seelam Jeevan Amos, Pavithra Venkateshaiah & KRS Sambasiva Rao

Received August 15, 2012; Revised September 05, 2012; Accepted October 17, 2012; Published November 13, 2012

Abstract:
The human malarial parasite Plasmodium falciparum is one of the world’s most devastating pathogen. Its capability to regulate its genes under various stages of its life cycle as well as under unfavourable environmental conditions has led to the development of vaccine resistant strains. Similarly, under drug pressure it develops mutations in the target genes. These mutations confer mid and high-level resistance to the antimalarial drugs. Increasing a resistance of malaria parasites to conventional antimalarial drugs is an important factor contributing to the persistence of the disease as a major health threat. This article reviews current knowledge of stage specific malarial targets, antimalarial drugs and the mutations that have led to the emergence of resistant strains.

Keywords: Malaria, Plasmodium falciparum, Antimalarial drugs, Mutations, Stage-specific protein targets.

Background:
Malaria is a life threatening disease, which is transmitted to public from one another exclusively by female Anopheles mosquitoes. The life cycle of Plasmodium is extraordinarily complex involving an invertebrate vector (mosquito) and a vertebrate host (human). Among the other, Plasmodium falciparum causes severe symptoms such as cerebral malaria and finally death. This disease is present in 106 countries and among these 99 have ongoing transmission of malaria. According to WHO (World Health Organization) estimation there were 216 million malaria cases was reported worldwide and among this 6, 55,000 persons were dead in 2010. 86% of the victims were children under 5 years of age, and 91% of malaria deaths occurred in the WHO African Region. Malaria mortality rates have fallen by 5.3% in global context in 2010 [1] http://www.who.int/malaria/world_malaria_report_2011/WMR2011_factsheet.pdf. The global incidence of malaria is mainly caused by four Plasmodium species. They are Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae.

Life cycle in brief
Life cycle of malarial parasite can be dividing into three stages (1) Exoerythrocytic stage (2) Intraerythrocytic stage and (3) Sporogonic stage. Among these first two stages are completed in humans and next one is in mosquitoes. Infection of Plasmodium is initiated as sporozoites (Exoerythrocytic Stage), they are injected into peripheral blood stream through the saliva of a feeding mosquito. These sporozoites are carried to the liver and invade hepatocytes through the circulatory system. After that it forms merozoites and enters into the blood stream and infects the erythrocytes (Intraerythrocytic), which is a pathogenic stage of malaria. Digestion of Hemoglobin is the major catabolic process of Plasmodium sps in merozoitic stage [2], mature merozoites can form trophozoites and these can form gametocytes or again invade into fresh erythrocytes. Plasmodium completes its life cycle in humans and enters into mosquitoes gut by blood meal for sexual cycle which is sporogonic and enters into salivary gland, ready to infect another human being.
Stage specific protein targets
The protein targets of P. falciparum from sporozoites (the infectious form injected by the mosquito), merozoites (the invasive stage of the erythrocytes), trophozoites (the form multiplying in erythrocytes), and gametocytes (sexual stages) of the human malaria parasite are tabulated Table 1 (see supplementary material). Genes involved in virulence and antigenic variation (for example, var, vir and rif genes) in Plasmodium falciparum are located in the subtelomeric regions of the chromosomes [3, 4].

Anti malarial drug- target- resistance
A limited number of chemotherapeutic agents for the treatment of malaria are available but the growing problem of drug resistance makes the treatment of malaria increasingly difficult [5]. Its control is hampered by increasing resistance of malaria to the available drugs [6]. Some of the anti malarial drugs available in market are mainly Quinine derivatives, antifolates and arylalcohols. Quinoline antimalarials, i.e. an active ingredient of Cinchona bark, which was used as antimalarial drug since seventeenth century [7]. Quinine requires thrice daily administration over 7 days, this can result in poor compliance. The dependence on raw material for its extraction and the availability of structural elucidation techniques leads to the development of fully synthetic chloroquine and later amodiaquine [8], which are inexpensive and more effective for a long time. Amodiaquine use has been limited since the mid 1980s, as it shows a high degree of efficacy [9]. The other antimalarial drugs structurally similar to chloroquine are Mefloquine and halofantrine, but resistance to these drugs was rapidly developed than chloroquine [10]. Additional limitations to these drugs usage of these drugs are occasionally neuropsychiatric disturbances for mefloquine and halofantrine, it can cause harm to the people with a history of heart disease [9].

Artemisinin the active constituent of the Chinese herb (Artemisia annua), which was used traditionally for treating several types of fevers, have been used increasingly over the past two decades [9, 11]. The derivatives of this include artemether, arteether and artesunate, they are metabolized to dihydroartemisinin the main active agent in the body to treat malaria. These drugs can act against gametocytes, the sexual stages of the parasite that infect mosquitoes. Lumefantrine is an aryl alcohol similar to mefloquine and halofantrine, and neurotoxicity was not reported in animal toxicology studies [12]. Antifolates are not derived from plants and synthesized through knowledge of cell biology and synthetic medicinal chemistry. Fully reduced folate cofactors are essential for nucleotide biosynthesis and amino-acid metabolism [13]. Antifolate used to treat malaria is 2, 4-diaminopyrimidine (Pyrimethamine) and Sulphadoxine, (sulphonamide) an inhibitor of dihydrofolate reductase (DHFR), and dihydropteroate synthase (DHPs) respectively. These enzymes are the part of folate pathway. Atovaquone/proguanil is another combination similar to that of sulphadoxine/pyrimethamine [13]. The hydroxynaphthoquinone atovaquone atovaquone interferes with mitochondrial electron transport. Common antibiotics acting against bacterial protein synthesis such as tetracycline, doxycycline and clindamycin inhibit parasite growth and are being used increasingly in combination with other antimalarial treatments to augment their activity [9].

Resistance
Chloroquine, which served as a cheap and reliable drug for decades, is becoming ineffective against Plasmodium falciparum in most tropical areas. Thus, there is a need to develop novel antimalarial agents that are effective against drug-resistant malarial parasites [14]. Drug development efforts generally aim for structurally unrelated compounds that work through new, independent mechanisms of action to existing antimalarial agents. Chloroquine and other derivatives such as amodiaquine, mefloquine, quinidine, quinacrine are potent inhibitors of heme polymerization. Target for the Chloroquine is the lysosome or food vacuole of the parasite; it interferes in the detoxification of haemoglobin. Pfmdr1 gene located on chromosome 5 of P. falciparum, encodes a P glycoprotein of 160 kDa which plays a role in drug efflux [15]. Pfmdr1 gene at codons 86, 184, 1034, 1042 and 1246 have been proposed to be associated with chloroquine resistance [16]. N 86Y mutation in pfmdr1 seems to be playing some role in the chloroquine resistance but it is unclear, pfcr is located on chromosome 7 and encodes for a protein named as P. falciparum chloroquine resistance transporter protein (PfCRT), this 36 kb membrane protein localizes to the parasite digestive vacuole (DV), the site of CQ action K76T mutation in pfcr has been found in all the chloroquine resistant parasites. Besides K76T mutation in pfcr, mutations at codon 72, 74, 75, 97, 220, 271, 326, 356 and 371 have also been found to be associated with chloroquine resistance [17]. Concomitantly associated with increased sensitivity to mefloquine and halofantrine [18-38] because of the 1042D and 1034C/1042D/1246Y alleles are associated with increased resistance to quinine and increased sensitivity to mefloquine and artemisinin drugs. The increased copy number of the Pfmdr1 gene in plasmodium falciparum leads to treatment failure with mefloquine [19, 20].

After the failure of chloroquine, Sulphadoxine-pyrimethamine is used as a second line of drug to treat uncomplicated chloroquine resistant falciparum malaria cases. Use of SP is limited for pregnant women during the early trimester [21, 22]. Sulphadoxine and pyrimethamine inhibit the enzymes dihydropteroate synthase and dihydrofolate reductase, respectively, involved in folate pathway. The mutation at codon 108 of P. falciparum DHFR S108N reduces the sensitivity of the pyrimethamine. The parasite isolates which showed pyrimethamine resistance, were found to contain this mutation and other mutations at codons 51 (N51I), 59 (C59R) and 164 (I164L)] were associated with S108N mutation. Majority of Indian isolates were found to contain double DHFR mutations (C59R+S108N) [24]. Most of the mutation in dihydropteroate synthase are at codons 436 (Ser to Ala/ Phe), 437 (Ala to Gly), 540 (Lys to Glu), 581 (Ala to Gly) and 613 (Ala to Ser/ Thr). A 437G is the key point mutation in DHPS; it is similar to S108N mutation in DHFR. A single DHFR mutation or double DHFR mutations alone will not cause SP treatment failure but that double DHFR mutations plus a single DHPS mutation or triple DHFR mutations alone can cause higher level of SP resistance [24, 25]. Artemisinin was another antimalarial drug adopted by several countries; it inhibits the uptake of host hemoglobin. P. falciparum degrades host hemoglobin in an acidic digestive vacuole in a mid ring stage and reaches a peak in the mid trophozoite stage [17]. Artemisinin distributes like BODIPYthapsigargin to membranous structures in the cytoplasm of parasites, and does not localize to the parasite...
BIOINFORMATION

food vacuole [26]. Artemisinin resistance would be calamitous for global malaria control. Artemisinin resistance is observed because of the polymorphisms in the Plasmodium falciparum merozoite genes encoding the surface proteins of (MSP-1 and MSP-2) and the glutamate-rich protein (GLURP). The point mutations in the PIMDR1 gene at positions N86Y, S1034C, N1042D, and D1246Y, but the mutant codon Y184F was found to be responsible for resistance against Artemisinin. Sporadic point mutations noted in the sequence of PSEERA gene revealed that mutations at I89T, N465S, and E847K are also seen in several field isolates. The PSEERA L263E and S769N polymorphisms, proposed to confer artemisinin resistance, but these two mutations were not detected in fields [27] (see supplementary material).

Amodiaquine, artemisinin-based combination therapy (ACT), introduced in 2001has the World Health Organization recommended ACTs as the first-line treatment for uncomplicated malaria. The mode of action of the combination therapy appears to be similar, and known to be concentrated in the parasite’s lysosome like Chloroquine(CQ) [28]. Most countries have now adapted to either Artemether LumeFanalum (AL) or ArteSunate (AS) and AmodiaQuine (AQ) as their first-line ACT, AQ is a 4-aminooquinoline related to chloroquine (CQ), and Although CQ resistance is now widespread across the world, the efficacy of AQ is variable in treatment trials [29]. A mutation from 76K-T of the P. falciparum chloroquine resistance transporter (PfCRT) gene is associated with resistance to both CQ and AQ [30]. Amplification of Pfmdr1 gene modulate susceptibility to the artemether-LumeFanalum ACT, leading to poor treatment response

Drugs that are potent inhibitors of heme polymerization, such as amodiaquine, mefloquine, quinidine, quinacrine, and chloroquine, competed well, although quinine competed to a lesser extent. Mefloquine is a lipophilic quinoline alcohol which is in wide clinical use. Like chloroquine and quinidine, it also binds to heme polymer in a heme-dependent fashion and diminishes binding of quinolines associates with hemozoin. Mefloquine and a protease inhibitor blocks heme release in the food vacuole [31]. Chloroquine accumulates in food vacuole and is bound to free heme and results in the inhibition of formation of hemozoin. Over expression of pfmdr1 related to the mafloquine resistance because it is also sharing some mechanism as other quinine derivatives [32]. Polymorphisms in the P. falciparum multidrug-resistant 1 (Pfmdr1) gene have concluded that its protein product, Pgh1, plays a role in modulating levels of resistance to several structurally unrelated drugs [18, 38]. All resistant parasites had the K76T mutation in the PFCRT gene. Some antimalarials, including artemisinin, are reported to inhibit hemoglobin uptake [34], but it is not clear if this is a direct effect, or a consequence of parasite killing. Artemisinin is highly potent against hemoglobin-digesting stages of malaria parasites [34, 37] than other hemoglobin-degrading drugs, but it is much less potent against other pathogens [35]. Falcipain-2 is the only cysteine protease hemoglobinase expressed early in erythrocytic parasite development, and knockout parasites have markedly diminished hemoglobinase activity in the early trophozoite stage [36]. These parasites exhibit a swollen vacuole phenotype, consistent with defective haemoglobin digestion, but the deletion is not lethal, apparently due to rescue by the expression of falcipain-2 and falcipain-3 beginning at the mid trophozoite stage [36].

Conclusion:
Antimalarial drugs play very important role in controlling of malaria at individual as well as at epidemiological level. Careful treatment can slow down the development of resistance against the available drugs, mostly due to regular usage leads to development of mutations in the target gene. It is advisable to check the efficacy of the drug at regular intervals so as to take a policy decision in advance on its continued usage in the field. Molecular surveillance can give an advanced indication that a particular drug is going to lose its efficacy in near future. However, molecular markers for several antimalarial drugs are yet to be identified and much improvement is required on the currently used method.

Acknowledgement:
Authors thank the Department of Biotechnology, Govt. of India for the financial assistance provided to carry out the project work. The authors would also like to thank Acharya Nagarjuna University, Guntur, India for providing the congenial environment and also for extending the lab facilities to carry out the work.

Reference:
[1] World Health Organisation. The World malaria report; Geneva, Switzerland. 2011
[2] Klenka M & Goldberg DE. Biochem. 2002 71: 275
[3] Hernandez-Rivas et al. Mol Cell Biol. 1997 17: 604 [PMCID: PM231785]
[4] Del Portillo HA et al. Nature. 2001 410: 839 [PMID: 11298455]
[5] World Health Organisation 2000 Report of the WHO expert Committee on malaria. WHO Tech.Rep.Ser.1-74.
[6] Greenwood BM et al. Malaria. 2005 365: 1487 [PMCID: PM21580534]
[7] Croft S, Drug Discov Today. 2001 15: 1151
[8] Ridley RG & Hudson AT, Exp Opin Ther Patents. 1998 8: 121
[9] Report No. 2001 WHO/CDS/ RBM/ 2001.33
[10] Wellens T & Plowe CV, J Infect Dis. 2001 184: 770 [PMID: 11517439]
[11] Li Y & Wu YL, Med Trop. 1998 58: 9 [PMID: 10212990]
[12] Skelton-Stroud P & Mull R, Med Trop. 1998 58: 77 [PMID: 10212907]
[13] Sherman I, Malaria: Parasite Biology. 1998 177: 184
[14] Oaks SC Jr et al. Malaria: Obstacles and Opportunities. National Academy Press, Washington, DC. 1991.
[15] Foote SJ et al. Celi. 1989 57: 921 [PMID: 2701941]
[16] Fidock DA et al. Mol Cell. 2000 6: 861 [PMID: 11090624]
[17] Slomianny C, Blood Cells. 1990 16: 369 [PMID: 2096983]
[18] Price RN et al. Clin Infect Dis. 2006 42: 1570 [PMID: 16652314]
[19] Pickard AL et al. Antimicrob Agents Chemother. 2003 47: 2418 [PMID: 12878499]
[20] Price RN et al. Lancet. 2004 364: 438 [PMID: 15286742]
[21] Korsneczy M et al. Antimicrob Agents Chemother. 2004 48: 2214 [PMID: 15155224]
[22] Leartsakulpanich U et al. M ol Biochem Parasitol. 2002 119: 63 [PMID: 11755187]
Ahmed A et al. Antimicrob Agents Chemother. 2004 48: 879
[PMID: 14982779]

Wang P et al. Mol Biochem Parasitol. 1995 71: 115 [PMID: 7630375]

Plowe CV et al. Infect Dis. 1997 176: 1590 [PMID: 9955372]

Eckstein-Ludwig U & Webb RJ, et al. Nature. 2003 424: 957 [PMID: 12931192]

Dondorp AM et al. N Engl J Med. 2009 361: 455 [PMID: 19641202]

Famin O & Ginsburg H, Biochem Pharmacol. 2002 63: 393
[PMID: 11853690]

Olliaro, P & Mussano P, Cochrane Database Syst Rev. 2003 2:
CD000016 [PMID: 12804382]

Djimde A et al. N Engl J Med. 2001 344: 257 [PMID: 11172152]

Sullivan DJ Jr et al. J Biol Chem. 1998 273: 31103 [PMID: 9813011]

Nishiyama Y et al. Nucleic Acids Symp Ser (Oxf). 2004 48: 163
[PMID: 17150529]

Hoppe HC et al. Antimicrob Agents Chemotherapy. 2004 48:
2370 [PMID: 15215083]

O’Neill PM et al. Molecules. 2010 15: 1705 [PMID: 20336009]

Kaiser M et al. Antimicrob Agents Chemother. 2007 51: 2991
[PMID: 17562801]

Siwally PS et al. Mol Biochem Parasitol. 2006 150: 96 [PMID: 16890302]

Klayman DL, Science. 1985 228: 1049 [PMID: 3887571]

Duraisingham MT et al. Mol Biochem Parasitol. 2000 108: 13
[PMID: 10802315]

Florens L & Washburn MP, et al. Nature. 2002. 419: 520
[PMID: 12368666]

Pinder JC, et al. J Cell Sci. 1998 111: 1831 [PMID: 9625746]

Holder AA, aMulti-immune Response and Multi-stage
Perspective 77–104 (ASM Press, Washington, 1996).

Coppel RL et al. Nature. 1983 306: 751 [PMID: 6361573]

Taylor HM et al. Infect Immun. 2001 69: 3635 [PMID: 11340024]

Kaneko O et al. Mol Biochem Parasitol. 2001 118: 223 [PMID: 11738712]

Dessens JT et al. EMBO J. 1999 18: 6221 [PMID: 10562534]

Deitsch, KW & Wellems TE, Mol Biochem Parasitol. 1996 76: 1
[PMID: 8919990]

Kyes SA et al. Proc Natl Acad Sci USA. 1999 96: 9333 [PMID: 10430943]

Edited by P Kangueane

Citation: Kasturi et al. Bioinformation 8(22): 1114-1118 (2012)

License statement: This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original author and source are credit
Supplementary material:

### Table 1: Stage specific Protein Targets in Plasmodium falciparum

| Stage          | Protein Type                                      | Protein Name |
|----------------|--------------------------------------------------|--------------|
| Merozoite      | Cell recognition and invasion                     | MCP1, MTIP   |
|                | Membrane Surface proteins                         | MSP1, MSP2, GPI |
|                |                                                   | MSP3, MSP6   |
|                | Erythrocyte Binding Protein                       | EBA175, EBA140/BAEBL |
|                | Recticulocyte Binding Protein                     | PFRH3        |
|                | Vacular Proteins                                 | A BRA, SERA, |
|                | Rhopty associated protein                         | RA P1,2 and 3, RhopH1,2,and 3, RESA, |
|                | Apical Organellar proteins*                      | AMA1,MAEBL,  |
| Sporozoite     | Membrane Surface Proteins                         | MSP8         |
|                | Circumsporozoit Protein                           | CSP          |
|                | Sporozoit Surface Protein                         | SSP2/TRAP,CTR |
|                | var Gene Proteins                                 | PFEPM1 25 isoforms |
|                | rif Gene Proteins                                 | rifins21 isoforms |
| Tropozoite     | Erythrocyte Membrane Protein                      | EMP2 and 3, Skeleton Binding Protein 1 |
|                | Exporting proteins                                | EXP1 and EXP2 |

*Proteins which are expressed in both merozoite and sporozoite stages

### Table 2: Target for the available drugs for Plasmodium falciparum: Responsible mutations

| Year | Drug       | Class            | Target       | Mutation                                      | References |
|------|------------|------------------|--------------|-----------------------------------------------|------------|
| 1945 | Chloroquine| 4, amino-quinolines | pfcrt         | K 76T SN P’s at 72, 74, 75, 97, 220, 271, 326, 356 & 371 | 16         |
|      |            |                  | pfdmr1       | N 86Y, SN P’s at 184, 1034, 1042 & 1246        |            |
| 1961 | Pyrimethamine| Diamino pyrimidine | pfldfr       | S108N SN P’s F50L, N 511, C59R and 164L        | 24, 25     |
|      |            |                  | pfdmr1       | Double mutation: C59R+*S108N                  |            |
|      |            |                  |              | Triple Mutation: N 511 + C59R + *S108N          |            |
| 1984 | Sulphadoxine| Sulfanamides      | pfldhs       | A 437G, S436A / F, L 540 E, A 581G andA 613 S/ T | 19, 18     |
|      | Meloquine  | Amino acids       | pfct          | K 76T                                         |            |
|      |            |                  | pfmdr1       | N 86Y, N 1042D & D1246Y                       |            |
| 1994 | Artemisinin| Sesquiterpene lactones | pfmdr1      | Y 184F N 86Y, S1034C, N 1042D, and D1246Y      | 26         |
|      |            |                  | pfcltr       | I88T, N 465S, E847K *L263E and *S769N         | 27         |
| 1999 | Artemether | Amino acids       | pfct          | K 76T                                         | 19         |
|      |            |                  | pfmdr1       | N 86Y, N 1042D & D1246Y                       |            |
|      | Lumefantrine| Sesquiterpene lactones | pfct        | 76K                                           | 16         |
|      |            |                  | pfmdr1       | 86N                                           |            |

*Key mutations play a role in Drug resistance. *Proposed responsible mutations but not seen in fields.

W H O had declared the drug as first-line treatment for the malaria in particular Year